Abstract: The present invention discloses a method of treating, preventing or ameliorating tumor growth by administering a therapeutic agent that selectively inhibits dipeptidyl peptidase including fibroblast activation protein and dipeptidyl peptidase 8/9 in combination with an immune checkpoint inhibitor. The method specifically discloses use of Talabostat in combination with an immune checkpoint inhibitor, its pharmaceutical composition and process of preparing such composition.

Abstract: The present invention discloses a method of treating, preventing or ameliorating tumor growth by administering a therapeutic agent that selectively inhibits dipeptidyl peptidase including fibroblast activation protein and dipeptidyl peptidase 8/9 in combination with an immune checkpoint inhibitor. The method specifically discloses use of Talabostat in combination with an immune checkpoint inhibitor, its pharmaceutical composition and process of preparing such composition.

Abstract: A method, non-transitory computer readable medium, and pharmaceutical assessment computing device that effectively reformulates and repositions pharmaceutical molecule data. With this technology, therapeutic area data comprising a medical condition and pharmaceutical molecule data corresponding to the medical condition is obtained. The pharmaceutical molecule data comprises pharmaceutical molecule identifiers and usage data parameters with corresponding usage data values for each of the pharmaceutical molecule identifiers. Each of the usage data values is compared to a corresponding usage threshold value. Reformulation opportunities are determined for each of the pharmaceutical molecule identifiers comprising a usage data value that exceeds the corresponding usage threshold value.

Abstract: A method, non-transitory computer readable medium, and pharmaceutical assessment computing device that effectively assesses pharmaceutical data. With this technology pharmaceutical data for a candidate drug is obtained. The pharmaceutical data including a drug indication and a pharmaceutical value for a plurality of pharmaceutical parameters. Next, standard of care data including standard of care values corresponding to the obtained drug indication for the candidate drug is obtained and deviations between the pharmaceutical parameter values and the standard of care values is determined. A plurality of pharmaceutical assessment scores is assigned to each one of a plurality of pharmaceutical parameters based on the determined deviations. A target product profile for the candidate drag is provided based on the assigned plurality of pharmaceutical assessment scores.

Abstract: The present invention discloses a method of treating, preventing or ameliorating tumor growth by administering a therapeutic agent that selectively inhibits dipeptidyl peptidase including fibroblast activation protein and dipeptidyl peptidase 8/9 in combination with an immune checkpoint inhibitor. The method specifically discloses use of Talabostat in combination with an immune checkpoint inhibitor, its pharmaceutical composition and process of preparing such composition.

Abstract: A method, non-transitory computer readable medium, and pharmaceutical assessment computing device that effectively reformulates and repositions pharmaceutical molecule data. With this technology, therapeutic area data comprising a medical condition and pharmaceutical molecule data corresponding to the medical condition is obtained. The pharmaceutical molecule data comprises pharmaceutical molecule identifiers and usage data parameters with corresponding usage data values for each of the pharmaceutical molecule identifiers. Each of the usage data values is compared to a corresponding usage threshold value. Reformulation opportunities are determined for each of the pharmaceutical molecule identifiers comprising a usage data value that exceeds the corresponding usage threshold value.

Abstract: A rapid method and kit is provided for identifying the targets of biologically active small molecules to identify new drugs that are capable of specific therapeutic effects as well as to identify novel small molecules including agonists and antagonists that may bind selected targets.